Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 in Adult Subjects With Advanced Solid Tumors or Multiple Myeloma

Next Previous
Trial Profile

A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 in Adult Subjects With Advanced Solid Tumors or Multiple Myeloma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Navtemadlin (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Bone cancer; Carcinoid tumour; Cholangiocarcinoma; Colon cancer; Endometrial cancer; Glioblastoma; Head and neck cancer; Liposarcoma; Malignant melanoma; Mesothelioma; Multiple myeloma; Neuroendocrine carcinoma; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Prostate cancer; Rectal cancer; Renal cell carcinoma; Salivary gland cancer; Soft tissue sarcoma; Solid tumours; Thyroid cancer
  • Focus Adverse reactions; First in man
  • Sponsors Kartos Therapeutics

    • Most Recent Events

    • 21 Jun 2020 Results assessing the effect of KRT-232 exposure on MIC-1 fold change from baseline and evaluate baseline serum MIC-1 level as a covariate in a PD exposure-response (E-R) model using data from two trials (NCT02016729 and NCT01723020), were presented at the 25th Congress of the European Haematology Association.
    • 29 Jul 2019 Results published in the Investigational New Drugs
    • 04 Oct 2017 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top